The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis

Yan-yan Wang; Hui Lu; Zheng Zhao; Feng Huang

doi:10.1007/s11655-012-1212-x

Your Location：

Home >

Browse articles >

The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis

Updated：2021-08-27

- The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis
- Chinese Journal of Integrative Medicine Vol. 19, Issue 2, Pages: 98-103(2013)
- Affiliations：
  
  1. Department of Rheumatology, Chinese PLA General Hospital,Beijing,China
  2. Department of Nephrology, First Hospital Affiliated to General Hospital of PLA,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-012-1212-x
  CLC：
- Published：2013，
  
  Published Online：31 January 2013，
Scan for full text
Wang, Yy., Lu, H., Zhao, Z. et al. The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis., Chin. J. Integr. Med. 19, 98–103 (2013). https://doi.org/10.1007/s11655-012-1212-x

Yan-yan Wang, Hui Lu, Zheng Zhao, et al. The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis. [J]. Chinese Journal of Integrative Medicine 19(2):98-103(2013)
Wang, Yy., Lu, H., Zhao, Z. et al. The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis., Chin. J. Integr. Med. 19, 98–103 (2013). https://doi.org/10.1007/s11655-012-1212-x DOI：

Yan-yan Wang, Hui Lu, Zheng Zhao, et al. The efficacy and safety of Jitongning Capsule (脊痛宁胶囊) in patients with ankylosing spondylitis. [J]. Chinese Journal of Integrative Medicine 19(2):98-103(2013) DOI： 10.1007/s11655-012-1212-x.

摘要

To confirm the efficacy and safety of Jitongning Capsule 脊痛宁胶囊 in the treatment of ankylosing spondylitis (AS). A total of 120 AS patients with early-intermediate were randomly and equally assigned to Jitongning Capsule group and sulfasalazine group. Jitongning Capsule was orally taken 4.5 g per day and sulfasalazine was orally taken 2 g daily for 12 months. The primary endpoint was the proportion of patients achieving the Assessment in Ankylosing Spondylitis 20 (ASAS 20)

secondary end points included Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

Bath Ankylosing Spondylitis Functional Index (BASFI)

Bath Ankylosing Spondylitis Metrology Index (BASMI)

patient’s global assessment by VAS rating

spinal pain

general pain and night pain

erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Tumor necrosis factor-α (TNF-α)

interferon-γ (IFN-γ) and interleukin-4 (IL-4) in the peripheral blood mononuclear cells (PBMC) of AS patients were measured. A total of 111 patients completed the study. There were 58 patients in Jitongning group and 53 patients in sulfasalazine group. Both drugs showed mild and occasional side effects. After treated by Jitongning Capsule and sulfasalazine

the proportion of ASAS20 responders at 12 month was 72.41% (42/58) and 67.92% (36/53) respectively. Both Jitongning Capsule and sulfasalazine treatment induced significant decrease in the proportion of CD4+T cell and CD8+T cell expressing TNF-α and IFN-γ at 12-month of treatment compared with baseline values (P<0.05). Jitongning Capsule are effective in a setting close to real-life medical care with a sustained improvement in signs and symptoms of AS

and reduce cytokine levels in PBMC. It showed comparable effects to sulfasalazine.

Abstract

secondary end points included Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

Bath Ankylosing Spondylitis Functional Index (BASFI)

Bath Ankylosing Spondylitis Metrology Index (BASMI)

patient’s global assessment by VAS rating

spinal pain

general pain and night pain

erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Tumor necrosis factor-α (TNF-α)

and reduce cytokine levels in PBMC. It showed comparable effects to sulfasalazine.

关键词

ankylosing spondylitisJitongning CapsuleSulfasalazinecytokine

Keywords

ankylosing spondylitisJitongning CapsuleSulfasalazinecytokine

references

Yang CH, Huang F. Immunogenetics and pathogenesis of ankylosing spondylitis. Curr Immunol 2007;27:265–268.

Wang LS, Huang F. Biologic agent in inflammatory arthritis. Chin J New Drug (Chin) 2007;16:1149–1153.

Van der linden S, Valkenburg HA, Cats A, et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A propsposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361–368.

Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al.A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–2291.

Takatori H, Kanno Y, Chen Z, O’shea JJ. New complexities in helper T cell fate determination and the implications for autoimmune diseases. Mod Rheumatol 2008;18:533–541.

Zhu J, Liu XY, Huang F. Th1/Th2 balance and ankylosing spondylitis. Chin J Rheumatol (Chin) 2000;4:202–205.

Szántó S, Aleksza M, Mihály E, Lakos G, Szabó Z, Végvári A, et al. Intracytoplasmic cytokine expression and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis. J Rheumatol 2008;35:2372–2375.

Cañete JD, Martínez SE, Farrés J, Sanmartí R, Blay M, Gómez A, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000;59:263–268.

Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499–505.

François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases. Ann Rheum Dis 2006;65:713–720

Kim TJ, Kim TH, Lee HJ, Lee B, Robin Poole A, Inman RD. T-cell responses to versican in ankylosing spondylitis. Rheumatol Int 2011;31:191–195.

FULL TEXT LINK

More>

Views

1656

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effects of herbal compound 861 on collagen synthesis and degradation in rat mesangial cells exposed to high glucose

Anti-inflammatory effect of Qingwen Baidu Decoction (清瘟败毒饮) in sepsis rats

Effect of Xuebijing injection (血必净注射液) on systemic lupus erythematosus in mice

Clinical study on the treatment of knee osteoarthritis of Shen (肾)-Sui (髓) insufficiency syndrome type by electroacupuncture

Effects of Yinian Jiangya Decoction (颐年降压饮) containing serum on cytokines secretion of vascular endothelium of spontaneously hypertensive rats

Related Author

No data

Related Institution

Department of Gerontology, Beijing Friendship Hospital, Capital Medical University

Library of Guangzhou University of Chinese Medicine

Hospital of Guangdong University of Technology

Department of Clinical Laboratory, the First Affiliated Hospital of Guangzhou University of Chinese Medicine

Department of Cerebropathia, the First Affiliated Hospital of Guangzhou University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰